Cancer Treatment Centers of America: Clinical Trials
Learn More About This Topic: Chat with Us | Email Us
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Summary
This study is for patients with metastatic breast cancer who are positive for BRCA1 or BRCA2 mutation and have received no more than one prior treatment for metastatic disease. This study will assess the efficacy and side effects of Veliparib.
For More Information:
Please contact one of our Oncology Information Specialists at 1-800-615-3055 to learn more about this clinical trial. Oncology Information Specialists are available 24 hours a day, 7 days a week, 365 days a year.
